Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.

ABSTRACT: As new treatment approaches, both immunotherapy and targeted treatments have been used in the clinical treatment of cancers. These therapies are different from traditional surgery, chemotherapy and radiotherapy. Use of a combination of immunotherapy and targeted treatments may improve tumor clearance. We investigated the feasibility of combining tyrosine kinase inhibitors (TKIs, targeted drugs) and SZU-101 (a novel TLR7 agonist synthesized by our laboratory). Thirteen different TKIs were combined with or without SZU-101 and studied to determine their effects on immunocytes. On the basis of the distinctive results, lapatinib and sunitinib were selected for further tumor-inhibition investigation and determination of the underlying mechanism. Interestingly, we found lapatinib to work better w

SUBMITTER: Gao N 

PROVIDER: S-EPMC5175151 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature